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Abstract
Podocyte loss and changes to the complex morphology are major causes of chronic
kidney disease (CKD). As the incidence is continuously increasing over the last dec-
ades without sufficient treatment, it is important to find predicting biomarkers.
Therefore, we measured urinary mRNA levels of podocyte genes NPHS1, NPHS2,
PODXL and BDNF, KIM‐1, CTSL by qRT‐PCR of 120 CKD patients. We showed a
strong correlation between BDNF and the kidney injury marker KIM‐1, which were
also correlated with NPHS1, suggesting podocytes as a contributing source. In
human biopsies, BDNF was localized in the cell body and major processes of podo-
cytes. In glomeruli of diabetic nephropathy patients, we found a strong BDNF signal
in the remaining podocytes. An inhibition of the BDNF receptor TrkB resulted in
enhanced podocyte dedifferentiation. The knockdown of the orthologue resulted in
pericardial oedema formation and lowered viability of zebrafish larvae. We found an
enlarged Bowman's space, dilated glomerular capillaries, podocyte loss and an
impaired glomerular filtration. We demonstrated that BDNF is essential for glomeru-
lar development, morphology and function and the expression of BDNF and KIM‐1
is highly correlated in urine cells of CKD patients. Therefore, BDNF mRNA in urine
cells could serve as a potential CKD biomarker.
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1 | INTRODUCTION
The “Greifswald Approach to Individualized Medicine (GANI_MED)”
aims at the development of individualized diagnosis, prevention and
therapy strategies for common diseases.1,2 Therefore, patient
cohorts were recruited and investigated under standardized and rou-
tine conditions. The cohort investigated in this report consisted of
patients diagnosed with chronic kidney disease (CKD).3
CKD mostly affects risk groups like patients suffering from dia-
betes mellitus or hypertension.4-6 The disease is characterized by a
decrease and subsequently by a loss of kidney function named end‐
stage renal disease. Loss of renal function can only be compensated
by renal replacement therapies like haemodialysis or transplantation.
Until today, CKD is not reversible and it is therefore important to
identify predictive biomarkers and possible target molecules allowing
early detection and prevention.
As it became obvious that podocytes are associated with the devel-
opment of CKD, this specific cell type was brought into the focus of
research.7,8 Podocytes, a post‐mitotic cell type, maintain the glomerular
filtration barrier by their unique cellular structure, which includes major
processes and foot processes covering the glomerular basement mem-
brane (GBM) in a zipper‐like fashion.9,10 Changes in these structures
lead to an impairment of glomerular function and are related to several
kidney diseases like focal segmental glomerulosclerosis (FSGS), minimal
change disease (MCD) and diabetic nephropathy (DN).
As podocytes share certain structural and molecular biological
characteristics with neurons, proteins involved in neuronal structural
and physiological maintenance11,12 are of great interest for podocyte
research and might play a potential role as biomarkers. One of those
neuron‐specific proteins is brain-derived neurotrophic factor (BDNF), a
neurotrophic factor which is involved in neurogenesis, neuronal sur-
vival,13,14 branching15,16 and synaptic growth.17 Thus, Ernfors et al18
have already shown that BDNF plays a key role in neuronal develop-
ment, because heterozygous knockout (KO) mice showed decreased
neuronal development and homozygous KO mice often die directly
after birth. It has already been shown that BDNF binds to 2 different
receptors—TrkB and p75, that are involved in cell survival and dif-
ferentiation processes.19,20 Recently, it has been reported that BDNF
and TrkB are expressed in podocytes in vivo, being essential for actin
polymerization and cell survival.21 As the actin cytoskeleton plays an
important role for podocyte morphology and adhesion in vivo, and
podocyte detachment is a major event in glomerulopathies, we
investigated the expression of BDNF in cells appearing in the urine
of patients suffering from CKD in an attempt to find out whether
BDNF could be a suitable marker for the detection of DN.
As a second potential biomarker for glomerulosclerosis, we chose
Hepatitis A virus cellular receptor 1 (HAVCR1) or kidney injury mole-
cule‐1 (KIM-1), a transmembrane protein that is not or at very low
levels expressed in healthy kidneys.22-25 Interestingly, Zhao et al26
found KIM-1 being up‐regulated in parietal epithelial cells and dedif-
ferentiated podocytes of diabetic rats. Furthermore, recent findings
show that the expression of KIM-1 reduces the negative effects of
acute kidney injury by inducing phagocytosis.27 Therefore, we
selected KIM‐1 to proof whether it could be used as a potential
glomerular biomarker.
To study the influence of BDNF on podocyte development and
glomerular morphology in vivo, we took larval zebrafish as a well‐
established model organism. The zebrafish larva is ideal for podocyte
research28-30 as it develops a functioning glomerulus during 48‐
56 hours post‐fertilization (hpf),31,32 which can be studied directly in living
larvae by 2‐photon microscopy (2‐PM).28,33,34 Moreover, by the use of
the morpholino technology, specific proteins can easily be knocked down.
Zebrafish express a bdnf orthologue, whose amino acid sequence
is 91% identical to human BDNF.35 Although the BDNF sequence is
rather conserved among these species, little is known about the func-
tion of bdnf in the zebrafish pronephros. A recent study has shown
that there is a beneficial, microRNA‐mediated effect on actin polymer-
ization in adriamycin‐induced podocyte damage emphasizing the
important role for BDNF in kidney homoeostasis.21
Our study shows that the mRNA expressions of BDNF, a newly
identified podocyte gene, and of KIM-1, an injury‐induced protein,
are highly correlated in urine cells of CKD patients and secondly that
the expression is associated with DN. Moreover, we show the
importance of BDNF for glomerular function in zebrafish larvae and
in isolated murine glomeruli.
2 | METHODS
2.1 | Study participants
Participants were recruited in the GANI_MED nephrology cohort.3
All participants signed informed written consent forms. The study is
consistent with the principles of the declaration of Helsinki, as
reflected by an a priori approval of the Ethics Committee of the
University of Greifswald.
2.2 | Clinical sample collection
A total of 120 urine samples were collected from participants who
had known CKD with or without hypertension and/or diabetes. We
used 50‐100 mL morning urine. Only in 5% of cases, the urine vol-
ume was <50 mL. Unfortunately, the HbA1c value of 1 patient was
not available. The time period from urine voiding until processing
never exceeded 4 hours, as we found out that in this time viable
cells could still be cultivated.
2.3 | Urine processing
Urine was centrifuged in a 50 mL centrifuge tube at room temper-
ature (RT) for 3 minutes at 2100 g. The urine pellet was resus-
pended in 1 mL phosphate‐buffered saline (PBS), transferred to a
1.5 mL centrifuge tube and then centrifuged at 12 000 g for 1 min-
ute at RT. The supernatant was discarded. The washed urine pellet
was resuspended in 900 μL Phenol/Guanidine‐based Qiazol lysis
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reagent (Qiagen, Hilden, Germany) and then short‐term stored at
−20°C until use.
2.4 | Kidney specimens
Kidney tissue for immunofluorescence was obtained by percuta-
neous renal biopsy from patients undergoing diagnostic evaluation.
Biopsies from 2 subjects with diagnosed DN were investigated. The
histopathological diagnosis included the following: diabetic glomeru-
losclerosis (patient 1) and FSGS with tubular changes (patient 2).
Control kidney tissue was taken from normal kidney parts of a renal
tumour surgery patient. The clinical‐functional diagnosis included the
following: slight restriction in GFR and arterial hypertrophy. An
informed consent was obtained from the donor.
2.5 | Podocyte de‐/differentiation assay
All animal experiments were performed in accordance with national
animal protection guidelines that conform to the National Institutes
of Health Guide for the Care and Use of Laboratory Animals and
were approved by the local governmental authorities. The podocyte
dedifferentiation assay was performed as described by Kindt et al.36
Glomeruli were treated with ANA‐12 (1‐100 μmol/L, Sigma‐Aldrich).
After 6 days, the cyan fluorescent protein (CFP) intensity was quan-
tified. Therefore, z‐stacks of 50 to 80 glomeruli were recorded with
the aforementioned confocal laser scanning microscope. Mean fluo-
rescence intensity per glomerulus was calculated after background
correction. Half maximal inhibitory concentrations (IC50) were calcu-
lated by fitting the data to a sigmoidal dose‐response regression
curve using Prism 5.01 (GraphPad Software, San Diego, CA, USA).
RNA sequencing was performed as previously described.37
2.6 | Zebrafish strains
The following zebrafish strains were used: ET (Tg(wt1a:eGFP);
mitfaw2/w2; roya9/a9), CADE (Tg(fabp10a:DBP‐eGFP); mitfaw2/w2;
roya9/a9).38 All zebrafish strains were raised, mated and maintained in
E3 medium at 28.5°C, as previously described.30,39
2.7 | Morpholinos injection
Translation‐blocking bdnf morpholinos (bdnfMO) were manufactured
by Gene Tools LCC (Philomath, OR, USA). As negative control, we
used standard control morpholinos (CtrlMO) offered by Gene Tools.
The morpholinos were diluted to 1 mmol/L. A volume of approxi-
mately 3 nL per zebrafish was injected into 2 to 4‐cell stage fertil-
ized eggs using a microinjector (Transjector 5246, Eppendorf,
Hamburg, Germany).
2.8 | Immunohistology
Immunohistology for cryosections was performed as described
previously.39,40
2.9 | Zebrafish in vivo microscopy
In vivo imaging was performed as previously described.28,34,40
2.10 | Statistical analysis
Urine expression data were log‐transformed for all correlation anal-
yses. Associations between potential biomarkers were assessed
using Pearson correlation followed by the Benjamini‐Hochberg pro-
cedure. Comparisons between groups were performed as indicated.
All comparisons between 2 groups concerning zebrafish experi-
ments were done with the Mann‐Whitney U test. All statistical
analyses were performed using LABMAT version 2013 and SPSS
V. 21.
3 | RESULTS
3.1 | Baseline characteristics of patients
To identify individual prognostic biomarkers for CKD, we analysed a
panel of potential urinary biomarkers in 120 GANI_MED renal study
participants. The baseline characteristics are shown in Table 1. The
investigated patient group consisted of 45 women (37.5%) and 75
men (62.5%) with a mean age of 64.3 years. All patients were
afflicted with CKD. The group included 33 diabetes patients and 75
dialysis patients. Mean estimated glomerular filtration rate (eGFR)
was 23.2 mL/min/1.73 m2, and 110 patients had an eGFR less than
60 mL/min/1.73 m2. The mean urinary albumin‐to‐creatinine ratio
(uACR) was 1245 mg/g. The diabetic group consisted of 19 male and
14 female patients, whereas the non‐diabetics included 55 men and
31 women. For one study participant, there was no information
about the diabetic status. The mean age was 65.9 years in diabetics
and 63.6 years in non‐diabetics. The diabetic patients had a mean
eGFR of 23.9 mL/min/1.73 m2 compared to 22.7 mL/min/1.73 m2 in
non‐diabetic patients. This difference was not statistically significant.
There was also no statistically significant difference concerning
TABLE 1 Patient characteristics
Variables Total Diabetics
Non‐
diabetics
n 120 33 86
Sex (m/f) 75/45 19/14 55/31
Mean age (y) 64.3 ± 15.7 65.9 ± 13.3 63.6 ± 16.5
Mean eGFR mL/min/
1.73 m2
23.2 ± 20.9 23.9 ± 16.1 22.7 ± 22.4
eGFR<60 mL/min/
1.73 m2
110/120 32/33 77/86
Mean UACR (mg/g) 1245 ± 2199 1531 ± 2654 1149 ± 1994
Dialysis 75/120 16/33 59/86
m = male; f = female; eGFR = estimated glomerular filtration rate,
UACR = urinary creatinine‐albumin ratio.
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the uACR, which was 1531 mg/g in diabetics and 1149 mg/g in
non‐diabetics. The group of diabetics included 32 patients with an
eGFR lower than 60 mL/min/1.73 m2 and 16 dialysis patients. The
group of non‐diabetics included 77 patients with an eGFR lower
than 60 mL/ min/ 1.73 m2 and 59 dialysis patients. Again, these dif-
ferences were not statistically significant.
3.2 | Correlations between urine mRNA levels
To investigate whether the mRNA levels were interrelated, we per-
formed a correlation analysis (Figure 1A) followed by the Benjamini‐
Hochberg procedure to determine statistical significance (Figure 1B).
We found a strong positive correlation between the expressions of
BDNF and KIM-1 (R = 0.87, P = 2.3 × 10−38, Figure 1C). Interest-
ingly, we also observed significant correlations between the expres-
sions of BDNF and the podocyte marker NPHS1 (R = 0.27,
P = .0025, Figure 1D) as well as between the expressions of KIM-1
and NPHS1 (R = 0.37, P = 3.7 × 10−5). These findings suggest that
podocytes might contribute to the population of BDNF‐ and KIM-1‐
expressing cells that are detectable in the urine. Additionally, there
were statistically significant correlations of the podocyte marker
NPHS2 with NPHS1 (R = 0.23, P = .011) as well as with CTSL-1
(R = 0.27, P = .0026). Other significant correlations were not
detected.
3.3 | Correlation analysis between urine mRNA
levels and clinical parameters revealed a negative
correlation between BDNF and uACR
To identify possible correlations between the investigated expres-
sions of urinary cell pellet mRNA species and clinical parameters, we
applied the Pearson correlation analysis corrected by the Benjamini‐
Hochberg procedure for the expression of the 3 podocyte markers
NPHS1, NPHS2, PODXL, the 3 biomarker candidates BDNF, KIM-1
and CTSL-1 and the clinical parameters eGFR, HbA1c and uACR.
These calculations revealed a significant negative correlation
between BDNF and uACR (P = .0046; Figure 1E). BDNF and eGFR
were not correlated with each other. Additionally, there was no sig-
nificant difference in BDNF expression between patients of different
CKD stages (Figure 1F). Furthermore, we did not find any significant
correlation between any of the other parameters in the observed
patient group (data not shown).
3.4 | Sex‐specific expression of BDNF and KIM-1 in
diabetic and non‐diabetic patients
As our cohort shows a typical frequency distribution of nephropa-
thies with the largest proportion suffering from diabetes, which is
F IGURE 1 Pearson correlation of urine
sediment mRNA expression. mRNA
expression was determined by qRT‐PCR
and normalized to GAPDH and the interrun
calibrator. Pearson correlations are shown
in the coloured boxes (A). Pearson
correlations after Benjamini‐Hochberg
procedure are shown in B, where grey
boxes indicate non‐significant correlations
and coloured boxes indicate significant
values. BDNF mRNA was significantly
correlated with mRNA of KIM-1 and
NPHS1 as also shown in C and D. KIM-1
mRNA is significantly correlated with
NPHS1 as well. BDNF mRNA is correlated
with uACR (E). There is no significant
difference in BDNF mRNA expression
between different CKD stages [stage <3:
n = 9, stage 3: n = 21, stage 4: n = 31,
stage 5: n = 58]; (F). [*P < .05; **P < .01;
***P < .001]
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one of the major causes of CKD, we investigated the expression of
BDNF and KIM-1 in diabetic and non‐diabetic patients (Figure S1).
We observed that the expressions of BDNF and KIM-1 were signifi-
cantly higher in diabetic than in non‐diabetic patients (P = .04 and
P = .02, respectively). The mean BDNF expression in diabetics
reached a value of 2.07, whereas non‐diabetics showed a lower
expression value of 1.30. Similar results were found for KIM-1. The
expression of KIM-1 was almost twice as high in diabetic patients
than in non‐diabetic patients (5.79 vs 2.97).
Interestingly, we found that the expressions of BDNF and KIM-1
were almost twice as high in females than in males (Figure S1), indi-
cating a sex‐dependent expression of BDNF and KIM-1. Thus, in
females suffering from DN, the expressions of BDNF and KIM-1
were 3.97 and 8.07, respectively, compared to 2.15 and 4.75,
F IGURE 2 Immunofluorescence staining of healthy human kidney sections for BDNF and KIM-1. Normal formalin‐fixed paraffin embedded
kidney sections were stained for BDNF (red), the podocyte marker protein synaptopodin (green) and nuclei (blue) by Hoechst. BDNF was
mainly expressed in the cell body and major processes of podocytes. There was moderate expression of synaptopodin in parietal epithelial
cells. [Scale bars upper panel = 50 μm. Scale bars lower panel = 10 μm] Kidney sections were also stained for KIM-1 (green), synaptopodin
(red) and nuclei (blue) by Hoechst. Very few KIM-1 positive cells were visible within the glomerulus. Only a few non‐glomerular cells were
stained. [Scale bar left picture = 100 μm. Scale bar right picture = 25 μm]
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respectively, in non‐diabetic females. The associations of BNDF and
KIM-1 with DN were not detected in males (Figure S1). There was a
statistically significant difference in BDNF mRNA expression between
female and male diabetics but not between female and male non‐
diabetics. In contrast, KIM-1 mRNA expression did not significantly
differ between female and male diabetics or non‐diabetics.
3.5 | BDNF and KIM-1 expressions are up‐regulated
in podocytes of patients with DN
As described previously, BDNF is expressed in a range of different
tissues and cell types. On the basis of our finding that the urine
mRNA levels of BDNF and the podocyte‐specific marker NPHS1
were statistically associated with each other, we investigated the
expression of BDNF in human glomeruli by immunofluorescence
staining. As shown in Figure 2, BDNF was expressed in glomeruli of
normal human kidney sections, especially in podocytes and to some
extent also in parietal epithelial cells. As the localization of synap-
topodin was mainly restricted to podocyte foot processes and no
co‐localization was found between synaptopodin and BDNF in podo-
cytes, we conclude that BDNF is mainly localized in the major
processes and in the cell body of podocytes. This was confirmed by
co‐staining with the slit diaphragm protein nephrin (Figure S3). In
renal biopsies from patients suffering from DN, we found an up‐reg-
ulation of the fluorescence intensity of the remaining podocytes as
identified by co‐staining with synaptopodin (Figure 3). The sub-
podocyte space was lost in these biopsies. Confirming these findings,
microarray analysis of glomeruli from patients suffering from DN
showed a significant 2.0‐fold enhanced expression of BDNF and a
1.3‐fold enhanced expression of its receptor TrkB compared to
F IGURE 3 Immunofluorescence staining of human diabetic nephropathy (DN) kidney sections for BDNF. Formalin‐fixed paraffin embedded
DN kidney sections were stained for BDNF (red), synaptopodin (green) and nuclei (blue) by Hoechst. Fewer BDNF‐expressing cells were found
in glomeruli of DN kidney sections than in healthy kidneys from Figure 2. Cells still expressing the podocyte marker protein synaptopodin
show an enhanced BDNF intensity (magnification 1 and 2). [Scale bars upper panels = 50 μm. Scale bars 1/2 = 10 μm]
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glomeruli from control individuals. Moreover, we further confirmed
the increase of BDNF expression (1.2‐fold) in protein‐overload
experiments in cultured murine podocytes (Figure S4). In contrast to
BDNF, KIM-1 was never observed in podocytes and rarely found in
other cells of normal glomeruli (Figure 2). However, in patients with
DN, a strong up‐regulation of KIM-1 in podocytes was detected (Fig-
ure 4). Additionally, sequencing data of glomeruli from our dediffer-
entiation assay36 revealed a 139‐fold increased Kim‐1 expression in
3‐day cultivated glomeruli compared to freshly isolated glomeruli.
3.6 | BDNF stabilizes podocyte differentiation in
cultured glomeruli
We recently established a novel assay to study podocyte de‐/differ-
entiation in isolated glomeruli of mice expressing CFP under control
of the Nphs1 promoter.36 As podocytes of isolated glomeruli sponta-
neously dedifferentiate in cell culture accompanied by a decrease in
Nphs1 expression, we used the Nphs1‐dependent CFP expression to
quantify podocyte dedifferentiation. Isolated glomeruli were incu-
bated with various concentrations (1‐100 μmol/L) of the selective
TrkB inhibitor ANA‐12. After 6 days, CFP intensity was decreased
concentration‐dependently by ANA‐12 with an IC50 value of
19.6 μmol/L (Figure S2), indicating an involvement of BDNF in podo-
cyte differentiation.
3.7 | The knockdown of BDNF induces proteinuria
in zebrafish larvae
To study the function of bdnf in vivo, we performed a bdnf knock-
down (KD) with specific morpholinos. To this end, we generated a
F IGURE 4 Immunofluorescence staining of human diabetic nephropathy (DN) kidney sections for KIM-1. Formalin‐fixed paraffin embedded
DN kidney sections were stained for KIM-1 (red), synaptopodin (green) and nuclei (blue) by Hoechst. A significant increase in the KIM‐1
expression was found in podocytes as well as in other epithelial cells. Higher magnifications are shown in 1 and 2. [Scale bars upper
panel = 50 μm. Scale bars lower panel = 75 μm. Scale bars 1/2 = 10 μm]
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translation‐blocking morpholino (bdnfMO). Three days after injec-
tion of the bdnfMO, 82.7 ± 2.0% of the zebrafish larvae had
developed severe pericardial oedema (arrow in Figure 5A), a hall-
mark of impaired kidney function. In contrast, only 1.3 ± 0.8% of
CtrlMO‐injected larvae developed pericardial oedema (Figure 5A,B).
In addition, bdnfMO‐injected larvae were less viable (72.9 ± 7.1%)
compared with larvae injected with CtrlMO (93.6 ± 6.0%) (Fig-
ure 5B). To investigate whether the pronephros of the zebrafish lar-
vae was affected by the KD of bdnf, we used the transgenic zebrafish
strain CADE expressing an eGFP‐tagged vitamin D‐binding protein in
F IGURE 5 Bdnf knockdown in zebrafish larvae leads to pericardial oedema formation, impaired glomerular filtration and down‐regulation of
podocyte‐specific genes. Bdnf morpholinos (bdnfMO) and control morpholinos (CtrlMO) were injected in ET zebrafish eggs. Brightfield pictures
were taken 3 dpf (A; a and b) and 6 dpf (A; e and f). bdnfMO‐injected larvae exhibit a higher rate of pericardial oedema development and a
lower viability than normal controls (B). Morpholino injection in CADE larvae reveals an impairment of glomerular filtration barrier function in
bdnfMO‐injected larvae 3 dpf (A; c) and 6 dpf (A; g) compared to CtrlMO‐injected larvae (A; d and f). The knockdown of bdnf was verified by
RT‐PCR (C). The down‐regulation of the podocyte marker nphs2 was verified on the mRNA level by RT‐PCR (C) and qRT‐PCR (D). Expression
levels were normalized to zgc:158463 in RT‐PCR and to zgc:158463 and eef1a1/1 in qRT‐PCR by the ΔΔCt method. [Scale bars = 500 μm]
[*P < .05, ***P < .001]
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the blood which cannot pass the intact filtration barrier. In contrast to
CtrlMO‐treated larvae, we observed a nearly complete loss of eGFP
fluorescence in the blood of bdnf KD larvae at 3 and 6 dpf (Figure 5A),
indicating leakage of the filtration barrier due to bdnf KD.
3.8 | BDNF is important for the proper morphology
of zebrafish glomeruli as well as for the expression of
nephrin and podocin
The KD of bdnf was verified by RT‐PCR showing reduced intensities
of the specific amplicon in bdnfMO‐injected larvae compared with
CtrlMO‐injected larvae (Figure 5C). Furthermore, bdnf KD larvae
showed reduced expression of nphs2 (podocin) in RT‐PCR analysis
(Figure 5C), which was confirmed by qRT‐PCR (Figure 5D). To study
the glomerular morphology, we stained cryosections of zebrafish lar-
vae, utilizing the ET strain that expresses eGFP specifically in podo-
cytes.28,30 After staining the F‐actin cytoskeleton with Alexa‐546
phalloidin, we observed significant changes in the morphology of the
glomeruli in response to the KD of bdnf. In addition to an enlarge-
ment of the glomerular tuft and Bowman's space, we observed a
reduced number of podocytes in bdnf KD larvae (3 dpf) in contrast
to CtrlMO‐treated zebrafish larvae (Figure 6A). Moreover, immuno-
histological staining for nephrin revealed a significant reduction of
the slit membrane protein due to the KD of bdnf in the zebrafish lar-
vae (Figure 6A).
3.9 | In vivo microscopy of bdnf knockdown larvae
Using in vivo 2‐photon microscopy (2‐PM) of bdnfMO‐injected ET lar-
vae, we found 2 different phenotypes. Both phenotypes showed
fewer podocytes and a dilated bowman's space (Figure 6Bc, aster-
isks) compared with controls (Figure 6Be,f). No major processes
could be distinguished in z‐stacks of glomeruli of KD larvae (Movie
S1), while control larvae showed a normal glomerular morphology
and well‐shaped major processes (Movies S3 and S4). The second
phenotype showed hindered fusion of the 2 glomeruli in the midline
(Figure 6Ba, white line, Movie S2), indicating disturbance of the
migration of the renal primordia (Figure 6A).
4 | DISCUSSION
Biomarkers from non‐invasive sources like urine are of growing
interest in CKD research, as they seem to be a promising diagnostic
tool for early detection of the disease. Conventional parameters like
proteinuria, cystatin C and creatinine are established markers of kid-
ney function, which are positively correlated with kidney dysfunc-
tion.41-45 Because they are only measurable at a relatively
progressed disease state, the establishment of markers for an earlier
disease state is needed. In this study, we investigated the mRNA
expression levels of potential predictive biomarkers for CKD in the
urine sediment. Previous studies identified a variety of predictive
biomarkers from urine sediment mRNA for non‐malignant kidney
diseases.46-49 In the present study, we found a strong and highly sig-
nificant positive correlation between BDNF mRNA levels and KIM-1
mRNA levels. KIM-1, which is endogenously expressed at a very low
levels, is a well‐established urinary biomarker for acute kidney injury
and is also known to be positively correlated with tubular and tubu-
lointerstitial injury as well as with glomerular damage.26,50-52 This is
in a very good agreement with our findings, as we could also detect
glomerular expression of KIM-1 by immunofluorescence staining and
in murine glomeruli of our podocyte dedifferentiation assay. There-
fore, BDNF mRNA levels might serve as a new potential biomarker
for glomerular kidney injury. Interestingly, we observed a statistically
significant up‐regulation of both mRNA species in diabetic patients
compared with non‐diabetic patients and for BDNF in a sex‐specific
manner. Sex specificity in kidney injury has been described ear-
lier,53,54 but seems to be relatively underestimated. BDNF mRNA
levels were also negatively correlated with uACR, indicating a possi-
ble influence on glomerular filtration barrier function. The non‐corre-
lation of urinary BDNF levels and eGFR may suggest that podocytes
with high levels of BDNF possibly detach at a lower rate. Podocyte
loss to a certain extent is a main event in glomerulopathies.55,56
Accordingly, we also found a positive correlation of KIM-1 and BDNF
with the podocyte marker NPHS1, suggesting that their expression
might be, at least partially, podocyte‐derived. Currently, there is no
known cellular mechanism directly linking KIM-1 and BDNF. Interest-
ingly, recent studies have shown that both proteins are involved in
autophagy, an important process for cell survival.57-59
Due to the findings described above, we further investigated the
role of BDNF in vitro and in vivo. To date, only one study21 has
addressed the role of BDNF in kidney function with a special focus
on podocytes. Li and coworkers revealed a critical role for BDNF in
podocyte cytoskeletal maintenance. They showed that BDNF TrkB‐
dependently up‐regulates actin polymerization in podocytes through
the regulation of the microRNA‐132/134 in vitro. Exogenous applica-
tion of BDNF led to more developed stress fibres and ramifications of
podocytes and could ameliorate podocyte damage by puromycin
aminonucleoside, adriamycin and protamine sulphate. They showed
that BDNF‐mediated TrkB activation has a stabilizing effect on podo-
cyte homoeostasis as well as a rescuing effect in different podocyte
injury models. These results suggest that the detection of BDNF in
the urine of patients might be an indication of stressed podocytes
that started to activate their “survival factor” BDNF.
As podocytes and neurons share some common features, it
was predictable that BDNF may also be expressed in both cell
types, as is the case for other proteins.11,12 In keeping with this
notion, we found that BDNF was expressed in the cell body and
in major processes of podocytes in human kidney biopsies. Surpris-
ingly, we did not see any co‐localization with synaptopodin, a
podocyte‐specific protein which is exclusively expressed in podo-
cyte foot processes, indicating that the localization of BDNF is
restricted to the cell body and the major processes.
Looking at sectioned kidney biopsies of patients, which were
diagnosed with DN, we observed less BDNF‐expressing podocytes,
but podocytes that still expressed BDNF showed an increased
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expression, which could serve as a potential biomarker in the diag-
nostic evaluation of renal biopsies. These results were confirmed by
microarray analyses of renal tissue from DN patients, where we have
also detected an up‐regulation of the BDNF receptor TrkB, underlin-
ing the importance of BDNF for podocyte homoeostasis.
As podocyte dedifferentiation is a critical step in the progression
of DN, we applied our well‐established dedifferentiation assay to
study the influence of BDNF on podocyte differentiation.36 We could
show that the inhibition of the TrkB receptor, which mediates for
BDNF signalling, led to decreased nephrin promotor activity and
therefore to increased podocyte dedifferentiation in murine glomeruli.
Only little is known about the effect of a BDNF KO on kidney
homoeostasis in vivo. As BDNF KO mice die directly after birth and
no kidney‐specific phenotypical impacts have been published,18 we
selected the zebrafish larva as model organism. Zebrafish larvae are
relatively easy to breed and show a glomerular morphology similar
to that of mammals with one glomerulus connected to two tubules
in their first functional state, the pronephros.31,32 Another advantage
is their applicability for in vivo microscopic techniques like 2‐PM
which can track changes in morphology and function.28,34 bdnf KD
larvae developed pericardial oedema as an indicator for an impair-
ment of the glomerular filtration barrier. This finding could be con-
firmed by a decrease in the intravascular eGFP intensity in bdnfMO‐
treated CADE larvae, also indicating a leaky filtration barrier.28,30 We
also found a reduced expression of the podocyte markers podocin
and nephrin, and a disrupted F‐actin structure in bdnfMO‐treated
larvae, which are suggestive of podocyte loss.
A positive influence of BDNF on the expression of podocyte
markers like nephrin has been shown before.21 We were able to
confirm this effect using 2‐PM microscopy, where two phenotypes
were visible: The first phenotype supports the hypothesis of podo-
cyte loss, with less podocytes visible on the glomerular tuft. The sec-
ond phenotype showed an unfused glomerulus, which might be a
hint for developmental delay. It has been demonstrated previously
that bdnf has beneficial effects on zebrafish kidney function and
podocyte homoeostasis in a model of kidney injury. In this model,
exogenous bdnf treatment rescued the expression of nephrin and
almost completely restored podocyte morphology.21
Here, we show that BDNF mRNA may potentially serve as a new
prognostic urinary biomarker for CKD. We also show that the
expression of BDNF in human podocytes is locally restricted to the
cell body and major processes. Furthermore, we give first insights
into the involvement of BDNF in podocyte dedifferentiation and into
its deregulation in DN. The KD of bdnf leads to impaired glomerular
filtration as well as to podocyte loss and/or hindered migration of
glomerular progenitors in an in vivo zebrafish model.
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